Why the study?
Wearable cardioverter defibrillators (WCDs) protect patients at elevated risk of sudden cardiac death only when worn, and historical limitations related to false alarms and patient adherence prompted the design of the ASSURE WCD and evaluation of its real-world safety and effectiveness.
Does the ASSURE wearable cardioverter-defibrillator safely and effectively convert ventricular tachycardia or ventricular fibrillation with low inappropriate shock rates in real-world patients at elevated risk of sudden cardiac death?
Cohort (n=21,612)
Yes
Does the ASSURE wearable cardioverter-defibrillator safely and effectively convert ventricular tachycardia or ventricular fibrillation with low inappropriate shock rates in real-world patients at elevated risk of sudden cardiac death?
In a real-world registry of over 21,000 patients, the next-generation ASSURE WCD demonstrated 100% VT/VF conversion efficacy, high daily adherence (23.1 h/day), and very low rates of false alarms and inappropriate shocks.
Answers are grounded in this paper and cite their sources.
Supports high real-world ASSURE WCD effectiveness; extends observational data but leaves open randomized outcome trials.
Introduction Wearable cardioverter defibrillators (WCDs) protect patients at elevated risk of sudden cardiac death (SCD) but are effective only when worn. The ASSURE WCD was designed to address historical limitations related to false alarms and patient adherence. The objective of this post‐approval study was to assess safety and effectiveness in a large, real‐world cohort. Methods The study population was comprised of patients meeting WCD indications who were fitted with the ASSURE WCD. The primary effectiveness endpoint was overall shock conversion success for ventricular tachycardia (VT) or ventricular fibrillation (VF) (performance goal ≥ 89%), and the primary safety endpoint was the incidence of inappropriate shocks (performance goal ≤ 0.0075 per patient‐month). Results Among 21 612 patients (mean age 64.0 years, 33.9% female), median daily use was 23.1 h/day (IQR 16.1–23.9) over 54 days (IQR 20–97). WCD indications included cardiomyopathy (63.8%), post‐myocardial infarction (19.3%), sustained VT/VF (11.9%) and ICD explant/other (5.0%). Both primary effectiveness and safety endpoints were met. All 303 VT/VF shock events in 261 patients (1.2%) were successfully converted, yielding an overall shock conversion success of 100% (95% CI: 98.8%–100%), with first‐shock success of 97.0% (95% CI: 94.4%–98.5%). The incidence rate of inappropriate shocks was 0.0065 per patient‐month (95% CI: 0.0057–0.0073). False‐positive alarms occurred in 6.0% of patients. The 90‐day Kaplan–Meier estimated risk of VT/VF was 3.4%, varying by WCD indication ( p < 0.001) but not by left ventricular ejection fraction ( p = 0.16). Conclusion In routine practice, the ASSURE WCD effectively terminated VT/VF with low false alarm and inappropriate shock rates and high patient adherence. Most VT/VF events occurred early during WCD wear. Collectively, these findings provide important contemporary evidence to inform the selection of patients who may benefit from WCD therapy during periods of elevated arrhythmic risk. Trial Registration NCT05135403.
No takes yet. Share an insight, caveat, or question.
Poole et al. (2026) conducted a cohort in Elevated risk of sudden cardiac death (cardiomyopathy, post-MI, sustained VT/VF, ICD explant/other) (n=21,612). ASSURE wearable cardioverter-defibrillator (WCD) vs. Pre-specified performance goals (≥89% conversion success; ≤0.0075 inappropriate shocks per patient-month) was evaluated on Overall shock conversion success for ventricular tachycardia (VT) or ventricular fibrillation (VF) (primary effectiveness) and incidence of inappropriate shocks (primary safety) (95% CI 98.8-100).
Synapse has enriched 10 related papers. Consider them for comparative context: